HALO logo

Halozyme Therapeutics (HALO) Operating Expenses

Annual Operating Expenses

$304.43 M
+$5.11 M+1.71%

December 31, 2024

Summary

Performance

1-Year Change

+1.71%

3-Year Change

+254.01%

5-Year Change

+39.61%

15-Year Change

+48.9%

HALO Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

79.95%
HALO annual total operating expenses is higher than 79.95% of companies in Healthcare sector

High & Low

All-time High

$304.43 M
HALO annual total operating expenses is currently at an all-time high

3-Year Low

$86.00 M
HALO annual total operating expenses is currently +254.01% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALOexpensesmetrics:

Annual Total Expenses

$463.85 M
HALO annual total expenses is $463.85 million

Annual Interest Expense

$18.09 M
HALO annual interest expense is $18.09 million

Annual Income Tax

$113.04 M
HALO annual income tax is $113.04 million

Annual Cost Of Goods Sold

$159.42 M
HALO annual cost of goods sold is $159.42 million

Quarterly Operating Expenses

$80.45 M
+$2.99 M+3.86%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+4.88%

3-Year Change

+10.31%

5-Year Change

+10.31%

HALO Quarterly Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

79.51%
HALO quarterly total operating expenses is higher than 79.51% of companies in Healthcare sector

High & Low

All-time High

$84.36 M
HALO quarterly total operating expenses is currently -4.63% below its historical high of $84.36 million

3-Year Low

$23.88 M
HALO quarterly total operating expenses is currently +236.87% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOexpensesmetrics:

Quarterly Total Expenses

$122.51 M
HALO quarterly total expenses is $122.51 million

Quarterly Interest Expense

$4.54 M
HALO quarterly interest expense is $4.54 million

Quarterly Income Tax

$41.20 M
HALO quarterly income tax is $41.20 million

Quarterly Cost Of Goods Sold

$42.05 M
HALO quarterly cost of goods sold is $42.05 million

Operating Expenses Formula

Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses

Annual Operating Expenses

$304.43 M
HALO annual total operating expenses is $304.43 million

Annual SGA

$154.34 M
HALO annual SGA is $154.34 million

Annual D&A

$81.31 M
HALO annual depreciation & amortization is $81.31 million

HALO Operating Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+1.7%+4.9%
3 y3 years+254.0%+10.3%
5 y5 years+39.6%+10.3%

HALO Operating Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+254.0%-4.6%+236.9%
5 y5-yearat high+280.7%-4.6%+351.8%
alltimeall timeat high-100.0%-4.6%+7892.0%

Halozyme Therapeutics Operating Expenses History

DateAnnualQuarterly
Dec 2024
$304.43 M(+1.7%)
$80.45 M(+3.9%)
Sep 2024
-
$77.46 M(+4.0%)
Jun 2024
-
$74.51 M(+3.5%)
Mar 2024
-
$72.01 M(-6.1%)
Dec 2023
$299.32 M(+18.2%)
$76.71 M(+5.2%)
Sep 2023
-
$72.93 M(-4.7%)
Jun 2023
-
$76.51 M(+4.6%)
Mar 2023
-
$73.17 M(+12.8%)
Dec 2022
$253.28 M(+194.5%)
$64.87 M(-17.2%)
Sep 2022
-
$78.36 M(-7.1%)
Jun 2022
-
$84.36 M(+228.4%)
Mar 2022
-
$25.69 M(+7.6%)
Dec 2021
$86.00 M(+7.5%)
$23.88 M(+10.3%)
Sep 2021
-
$21.66 M(+6.2%)
Jun 2021
-
$20.39 M(+1.6%)
Mar 2021
-
$20.07 M(+12.7%)
Dec 2020
$79.97 M(-63.3%)
$17.81 M(-8.4%)
Sep 2020
-
$19.45 M(-2.4%)
Jun 2020
-
$19.93 M(-12.6%)
Mar 2020
-
$22.79 M(-67.0%)
Dec 2019
$218.06 M(+3.3%)
$69.04 M(+42.5%)
Sep 2019
-
$48.43 M(-5.5%)
Jun 2019
-
$51.25 M(+3.9%)
Mar 2019
-
$49.33 M(-9.8%)
Dec 2018
$211.06 M(+3.2%)
$54.68 M(+8.5%)
Sep 2018
-
$50.40 M(-7.4%)
Jun 2018
-
$54.44 M(+5.6%)
Mar 2018
-
$51.53 M(-8.2%)
Dec 2017
$204.46 M(+3.9%)
$56.15 M(+18.6%)
Sep 2017
-
$47.32 M(-8.0%)
Jun 2017
-
$51.44 M(+3.8%)
Mar 2017
-
$49.55 M(-7.5%)
Dec 2016
$196.69 M(+47.6%)
$53.58 M(+17.8%)
Sep 2016
-
$45.46 M(-2.8%)
Jun 2016
-
$46.75 M(-8.2%)
Mar 2016
-
$50.91 M(+32.8%)
Dec 2015
$133.26 M(+15.2%)
$38.34 M(+1.3%)
Sep 2015
-
$37.84 M(+22.0%)
Jun 2015
-
$31.01 M(+18.9%)
Mar 2015
-
$26.08 M(-7.1%)
Dec 2014
$115.64 M(-10.3%)
$28.08 M(-1.4%)
Sep 2014
-
$28.49 M(+4.0%)
Jun 2014
-
$27.40 M(-13.5%)
Mar 2014
-
$31.66 M(+4.6%)
Dec 2013
$128.99 M
$30.28 M(-10.5%)
Sep 2013
-
$33.82 M(-4.2%)
DateAnnualQuarterly
Jun 2013
-
$35.29 M(+19.3%)
Mar 2013
-
$29.59 M(+15.8%)
Dec 2012
$94.86 M(+25.4%)
$25.55 M(+1.6%)
Sep 2012
-
$25.14 M(+16.0%)
Jun 2012
-
$21.66 M(-3.8%)
Mar 2012
-
$22.51 M(+8.3%)
Dec 2011
$75.67 M(+13.1%)
$20.78 M(+16.9%)
Sep 2011
-
$17.78 M(-10.7%)
Jun 2011
-
$19.91 M(+15.8%)
Mar 2011
-
$17.19 M(-16.4%)
Dec 2010
$66.90 M(-6.9%)
$20.57 M(+30.0%)
Sep 2010
-
$15.82 M(+3.5%)
Jun 2010
-
$15.28 M(+0.4%)
Mar 2010
-
$15.22 M(-19.7%)
Dec 2009
$71.82 M(+22.0%)
$18.96 M(+12.4%)
Sep 2009
-
$16.87 M(-8.7%)
Jun 2009
-
$18.46 M(+5.4%)
Mar 2009
-
$17.53 M(-12.2%)
Dec 2008
$58.87 M(+85.6%)
$19.96 M(+47.5%)
Sep 2008
-
$13.53 M(+5.9%)
Jun 2008
-
$12.77 M(+1.3%)
Mar 2008
-
$12.60 M(+12.2%)
Dec 2007
$31.71 M(+96.6%)
$11.24 M(+22.2%)
Sep 2007
-
$9.19 M(+42.2%)
Jun 2007
-
$6.47 M(+34.3%)
Mar 2007
-
$4.81 M(-4.7%)
Dec 2006
$16.13 M(+18.3%)
$5.05 M(+31.9%)
Sep 2006
-
$3.83 M(+8.9%)
Jun 2006
-
$3.52 M(-5.5%)
Mar 2006
-
$3.72 M(+3.0%)
Dec 2005
$13.64 M(+50.1%)
$3.61 M(-4.4%)
Sep 2005
-
$3.78 M(+27.3%)
Jun 2005
-
$2.97 M(-9.2%)
Mar 2005
-
$3.27 M(+29.4%)
Dec 2004
$9.09 M(>+9900.0%)
$2.53 M(-22.5%)
Sep 2004
-
$3.26 M(+56.2%)
Jun 2004
-
$2.09 M(+73.0%)
Mar 2004
-
$1.21 M(-217.0%)
Dec 2003
$0.00(0.0%)
-$1.03 M(-352.9%)
Sep 2003
-
$408.20 K(+9.5%)
Jun 2003
-
$372.90 K(+48.3%)
Mar 2003
-
$251.40 K(-532.7%)
Dec 2002
$0.00(-100.0%)
-$58.10 K(-326.1%)
Sep 2002
-
$25.70 K(+38.2%)
Jun 2002
-
$18.60 K(+35.8%)
Mar 2002
-
$13.70 K
Dec 2001
$48.50 K
-

FAQ

  • What is Halozyme Therapeutics annual total operating expenses?
  • What is the all time high annual operating expenses for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual operating expenses year-on-year change?
  • What is Halozyme Therapeutics quarterly total operating expenses?
  • What is the all time high quarterly operating expenses for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly operating expenses year-on-year change?

What is Halozyme Therapeutics annual total operating expenses?

The current annual operating expenses of HALO is $304.43 M

What is the all time high annual operating expenses for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual total operating expenses is $304.43 M

What is Halozyme Therapeutics annual operating expenses year-on-year change?

Over the past year, HALO annual total operating expenses has changed by +$5.11 M (+1.71%)

What is Halozyme Therapeutics quarterly total operating expenses?

The current quarterly operating expenses of HALO is $80.45 M

What is the all time high quarterly operating expenses for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly total operating expenses is $84.36 M

What is Halozyme Therapeutics quarterly operating expenses year-on-year change?

Over the past year, HALO quarterly total operating expenses has changed by +$3.75 M (+4.88%)